Developer docs
API playgroundTry for free, no card

Search company profiles

Organtech

Full company profile

uuid0038jjc

Namestring
Organtech
Legal namestring
株式会社オーガンテック
Websiteurl
organ-tech.jp
Company typeenum
Private
Founded yearint
2023
Descriptiontext

OrganTech, Inc. (株式会社オーガンテック) is a Tokyo-headquartered regenerative medicine company founded in 2008 by Professor Takashi Tsuji, built around the proprietary Organ Germ Method (器官原基法) developed in 2007. The technology reconstitutes functional organs by positioning epithelial and mesenchymal stem cells in a high-density compartmentalized 3D configuration, enabling regeneration of teeth, hair follicles, salivary glands, and lacrimal glands. The company operates three business lines: Bio-hybrid Tooth (a periodontal ligament-integrated dental implant), Hair Follicle Regeneration (a three-cell stem cell therapy for alopecia), and Three-dimensional Artificial Skin (a tension-loaded 3D skin model for pharmaceutical and cosmetics testing). All three programs rest on a single platform technology, with 37 patents (15 domestic, 22 international) and over 180 peer-reviewed publications in high-impact journals including Nature Communications, Scientific Reports, and Nature Protocols.

The company's revenue model is multi-pronged and still pre-commercial. Bio-hybrid Tooth is currently in a specified clinical research study at Minami Tohoku Medical Clinic (initiated February 2025, 4 patients enrolled, 3 evaluated at 24 weeks with successful osseointegration and no adverse events). Artificial skin technology is licensed to Kojima Bio for manufacturing and commercial sale to pharmaceutical, cosmetics, and healthcare companies. Hair follicle regeneration technology has been licensed domestically to an undisclosed Japanese partner for manufacturing rights, and research support services are provided to healthcare and medical enterprises. Pricing is not publicly disclosed across any segment. Target customer segments include dental clinics and oral healthcare providers, alopecia patients (the company cites 18 million androgenetic alopecia and 6 million telogen effluvium patients in Japan), pharmaceutical/cosmetics companies, and corporate R&D clients. QNova Inc. was engaged in August 2025 to pursue FDA 510(k) approval for the next-generation Bio-implant for US market entry.

Leadership transitioned in September 2024 with the appointment of Yoshio Shimo, former President and Chairman of Hino Motors (Toyota group), as Representative Director CEO, signaling a strategic pivot toward commercialization and international capital markets. CTO Miho Ogawa (PhD, biological engineering) and COO Yoshitake Yamaguchi (former Toshiba executive) round out the executive team. The company is venture-backed, having received investment from Kobayashi Pharmaceutical in February 2023 and completing an undisclosed fundraising round in June 2026 to support its next growth stage. The CEO has publicly stated NASDAQ listing as a future objective. The company targets the global dental implant market (~$4.9B in 2024, projected $8.4B by 2030 at ~10% CAGR) and the hair restoration market (projected to exceed $15B).

Short descriptiontext

OrganTech is a Tokyo-based regenerative medicine company developing organ regeneration technologies including the Bio-hybrid Tooth dental implant, hair follicle regeneration therapy, and 3D artificial skin, serving dental clinics, alopecia patients, and pharmaceutical companies through clinical research and technology licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine, organ regeneration, dental implants, hair follicle regeneration, artificial skin models
Industry4 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
Product category
Regenerative Medicine
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Bio-hybrid Tooth (Dental Implant) Products and Services
TypeHardware Sales
Description

Revenue from periodontal ligament-integrated dental implants (Bio-hybrid Tooth) targeting dental clinics and hospitals. Currently in clinical research stage with a specific clinical study initiated in February 2025 at Minami Tohoku Medical Clinic. Revenue model involves medical device manufacturing and sales, and clinical service fees.

organ-tech.jp
2Artificial Skin Licensing and Research Services
TypeLicensing Royalties
Description

Revenue from licensing tension-providing 3D artificial skin manufacturing technology to pharmaceutical, cosmetics, and healthcare companies for drug safety testing, efficacy screening, and disease model development. Research support services for hair care and hair loss product development using human dermal papilla cells are also provided.

organ-tech.jp
3Hair Follicle Regeneration Technology Licensing
TypeLicensing Royalties
Description

Revenue from licensing domestic manufacturing rights for hair follicle cell-derived components including the third cell type (hair follicle regeneration-supporting cells), targeting alopecia treatment applications. Clinical translation strategy is ongoing toward hair restoration therapies.

organ-tech.jp
4Research Support Services
TypeProfessional Services
Description

Corporate research and development support services leveraging OrganTech's extensive life sciences expertise, covering healthcare and medical domains. Services include artificial skin manufacturing support, functional molecule screening system development, hair care and hair loss product development support, and general healthcare product development consulting.

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

OrganTech develops and commercializes proprietary organ regeneration technologies built on its foundational Organ Germ Method (器官原基法), a 3D stem cell manipulation technique. Its commercial portfolio consists of three product lines: Bio-hybrid Tooth (periodontal ligament-integrated dental implants), Hair Follicle Regeneration therapy using a three-cell configuration, and tension-providing 3D Artificial Skin models for pharmaceutical and cosmetics testing. The company also offers research support and licensing services to corporate R&D clients in healthcare and life sciences.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Osseointegration confirmed in all 4 enrolled patients; 3 evaluated at 24 weeks showed natural tooth-like test values and no inflammatory adverse events (periotest values within natural tooth range of 2-5)
+3 more records
Product overview1 text field

OrganTech is a regenerative medicine company developing three core product lines based on its world-first organ regeneration technology: Bio-hybrid Tooth (dental implant with periodontal ligament), Hair Follicle Regeneration (hair loss treatment using stem cells), and Three-dimensional Artificial Skin (tension-loaded skin model for testing). The company operates as a platform of technologies anchored by the 'Organ Germ Method' developed in 2007, with all three products addressing quality of life (QOL) medical needs.

Product and service4 records
1Bio-hybrid Tooth (バイオハイブリッドトゥース)
CategoryMedical Device / Dental Implant
Description

A next-generation dental implant integrating a hydroxyapatite-coated titanium fixture with a regenerated periodontal ligament (periodontal ligament, cementum, and alveolar bone) derived from the patient's own residual tissue. It restores natural physiological tooth functions including shock absorption, proprioception, and immune defense that are absent in conventional osseointegration implants. Targeted at dental clinics, oral surgeons, and prosthodontists.

2Hair Follicle Regeneration (毛髪再生)
CategoryRegenerative Therapy / Hair Loss Treatment
Description

A regenerative therapy that reconstitutes functional hair follicles from a three-cell configuration: epithelial stem cells, mesenchymal dermal papilla cells, and a newly identified accessory mesenchymal cell (hair follicle regeneration-supporting cell) derived from the patient's own occipital hair. Designed for alopecia treatment including androgenetic alopecia, female pattern hair loss, alopecia areata, cicatricial alopecia, and drug-induced alopecia.

3Three-dimensional Artificial Skin (三次元人工皮膚)
CategoryLife Sciences Research Tool / In Vitro Testing Model
Description

The world's first 3D artificial skin model with applied mechanical tension, where epidermal and dermal cell orientation mimics natural skin and dramatically enhances cellular physiological function. Licensed to pharmaceutical, cosmetics, and healthcare companies for safety testing (skin irritation assays), high-sensitivity functional assays, mechanism analysis, and disease/damage model development.

4Research Support Services (研究支援)
CategoryResearch and Development Services / Consulting
Description

Contract research and development services for corporate clients in healthcare and medical domains. Includes artificial skin manufacturing support, functional molecule screening system development, hair care and hair loss product development support using human dermal papilla cells, and general healthcare product development consulting leveraging OrganTech's life sciences expertise.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1MID-G (Medical Innovation and Dental Growth)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-17
Description

OrganTech became a supporting member of MID-G, an organization that supports dental clinics in academic, educational, and business management areas. This partnership supports the company's Bio-hybrid Tooth go-to-market strategy.

organ-tech.jp
2RIKEN Center for Biosystems Dynamics Research (理化学研究所 生命機能科学研究センター)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-25
Description

A long-standing research collaboration with RIKEN BDR, where OrganTech's founder Takashi Tsuji led the Organ Induction Research Team from 2014-2024. Joint research has produced the Organ Germ Method and multiple organ regeneration breakthroughs including the discovery of the accessory mesenchymal cell essential for hair follicle regeneration, published in Biochemical and Biophysical Research Communications in 2026.

longevity.technology
3Kojima Bio Co., Ltd. (コージンバイオ社)
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-08-27
Description

Licensing agreement for three-dimensional artificial skin technology with Kojima Bio Co., Ltd., enabling the company to manufacture and commercialize OrganTech's tension-providing 3D artificial skin for pharmaceutical, cosmetics, and healthcare applications.

organ-tech.jp
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-26
Description

Partnership with US-based QNova Inc. to advance next-generation Bio-implant toward FDA regulatory approval and US market entry. QNova provides regulatory expertise and market access support for the FDA 510(k) pathway as a medical device.

5Hillside Akasaka Dental Clinic (ヒルサイド赤坂デンタルクリニック)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-08-20
Description

Clinical research site for next-generation Bio-implant in Tokyo, initiated August 2025 as part of OrganTech's multi-site clinical development strategy.

organ-tech.jp
6Undisclosed Japanese Partner (国内ライセンス先)
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-05-20
Description

Domestic manufacturing rights license for hair follicle cell-derived components including the third 'hair follicle regeneration-supporting' cell type for alopecia treatment applications.

organ-tech.jp
7Musashi Precision Co., Ltd. (武蔵精密工業株式会社)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-02-04
Description

Business partnership for joint R&D of automated manufacturing equipment for 3D artificial skin models. Musashi Precision contributes manufacturing automation expertise while OrganTech provides the artificial skin technology platform.

organ-tech.jp
8Minami Tohoku Medical Clinic / Brain Surgery Disease General Institute (南東北医療クリニック / 脳神経疾患研究所附属総合南東北病院)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-29
Description

Clinical research partnership for Bio-hybrid Tooth specified clinical study. Responsible physician Dr. Shohei Kasugai (formerly Tokyo Medical and Dental University) leads the study. The clinic conducted patient enrollment (completed October 2025) and reported positive interim results at 24-week evaluation for all 3 assessed patients.

organ-tech.jp
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Japanese 3D bioprinting company developing tissue-engineered products using its proprietary Kenzan method. Direct peer to OrganTech in 3D tissue engineering and biofabrication, with overlap in regenerative medicine product development in Japan.

TypeBroad incumbent
Description

Global leader in dental implants and restorative dentistry with extensive surgeon training, distribution, and brand recognition. Relevant broad incumbent in the dental implant market that OrganTech's Bio-hybrid Tooth would need to displace or differentiate against upon commercialization.

TypeDirect peer
Description

Japanese regenerative medicine company commercializing autologous tissue-engineered products (cartilage, skin, cornea). Direct peer in the regenerative medicine/QOL product space, sharing the same Japanese regulatory environment and commercialization model via cell-based therapies.

TypeDirect peer
Description

US-based 3D bioprinting company developing human tissue models for drug discovery and therapeutic applications. Comparable to OrganTech's 3D Artificial Skin program, both leveraging biofabrication to create human-relevant tissue models for pharma and cosmetics testing.

TypeBroad incumbent
Description

US-listed regenerative medicine company commercializing placental tissue allografts for wound healing and surgical recovery. Comparable to OrganTech as a broad regenerative medicine commercializer, though focused on a different tissue modality and existing US commercial scale.

TypeBroad incumbent
Description

Global medical device company with broad regenerative technology and tissue products portfolio including dermal regeneration templates. Comparable as a broad incumbent offering overlapping regenerative skin/tissue solutions, though at much larger scale and via different (scaffold-based) technology.

TypeDirect peer
Description

US-based biotech developing iPSC-derived hair follicle regeneration therapies for androgenetic alopecia. Directly comparable to OrganTech's Hair Follicle Regeneration program as both pursue cellular regeneration of hair follicles rather than transplantation or drugs.

TypeDirect peer
Description

A Japanese clinical-stage biotech developing tooth regeneration therapies using anti-USAG-1 antibody technology. Directly comparable to OrganTech as one of very few companies globally pursuing biological tooth regeneration, with overlapping target patient populations and similar pre-commercial stage.

9CellSeed
TypeDirect peer
Description

Japanese regenerative medicine company developing temperature-responsive cell cultureware and epithelial sheet products for regenerative applications. Comparable to OrganTech as a Japan-based regenerative medicine company pursuing cell-based tissue products in adjacent regenerative indications.

TypeEmerging player
Description

Korean stem cell therapeutics company commercializing Cartistem and other umbilical cord blood-derived stem cell products. Comparable to OrganTech as an Asian stem cell therapeutics developer with both regenerative and tissue-engineering programs targeting similar QOL indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Organtech

Regenerative Medicineorgan-tech.jp

OrganTech is a Tokyo-based regenerative medicine company developing organ regeneration technologies including the Bio-hybrid Tooth dental implant, hair follicle regeneration therapy, and 3D artificial skin, serving dental clinics, alopecia patients, and pharmaceutical companies through clinical research and technology licensing.

What Organtech does

OrganTech, Inc. (株式会社オーガンテック) is a Tokyo-headquartered regenerative medicine company founded in 2008 by Professor Takashi Tsuji, built around the proprietary Organ Germ Method (器官原基法) developed in 2007. The technology reconstitutes functional organs by positioning epithelial and mesenchymal stem cells in a high-density compartmentalized 3D configuration, enabling regeneration of teeth, hair follicles, salivary glands, and lacrimal glands. The company operates three business lines: Bio-hybrid Tooth (a periodontal ligament-integrated dental implant), Hair Follicle Regeneration (a three-cell stem cell therapy for alopecia), and Three-dimensional Artificial Skin (a tension-loaded 3D skin model for pharmaceutical and cosmetics testing). All three programs rest on a single platform technology, with 37 patents (15 domestic, 22 international) and over 180 peer-reviewed publications in high-impact journals including Nature Communications, Scientific Reports, and Nature Protocols.

The company's revenue model is multi-pronged and still pre-commercial. Bio-hybrid Tooth is currently in a specified clinical research study at Minami Tohoku Medical Clinic (initiated February 2025, 4 patients enrolled, 3 evaluated at 24 weeks with successful osseointegration and no adverse events). Artificial skin technology is licensed to Kojima Bio for manufacturing and commercial sale to pharmaceutical, cosmetics, and healthcare companies. Hair follicle regeneration technology has been licensed domestically to an undisclosed Japanese partner for manufacturing rights, and research support services are provided to healthcare and medical enterprises. Pricing is not publicly disclosed across any segment. Target customer segments include dental clinics and oral healthcare providers, alopecia patients (the company cites 18 million androgenetic alopecia and 6 million telogen effluvium patients in Japan), pharmaceutical/cosmetics companies, and corporate R&D clients. QNova Inc. was engaged in August 2025 to pursue FDA 510(k) approval for the next-generation Bio-implant for US market entry.

Leadership transitioned in September 2024 with the appointment of Yoshio Shimo, former President and Chairman of Hino Motors (Toyota group), as Representative Director CEO, signaling a strategic pivot toward commercialization and international capital markets. CTO Miho Ogawa (PhD, biological engineering) and COO Yoshitake Yamaguchi (former Toshiba executive) round out the executive team. The company is venture-backed, having received investment from Kobayashi Pharmaceutical in February 2023 and completing an undisclosed fundraising round in June 2026 to support its next growth stage. The CEO has publicly stated NASDAQ listing as a future objective. The company targets the global dental implant market (~$4.9B in 2024, projected $8.4B by 2030 at ~10% CAGR) and the hair restoration market (projected to exceed $15B).

Organtech firmographics

Firmographics
Name
Organtech
Legal name
株式会社オーガンテック
Website
https://organ-tech.jp
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
OrganTech is a Tokyo-based regenerative medicine company developing organ regeneration technologies including the Bio-hybrid Tooth dental implant, hair follicle regeneration therapy, and 3D artificial skin, serving dental clinics, alopecia patients, and pharmaceutical companies through clinical research and technology licensing.
Ownership category
akta.pro rank

Organtech industry classification

Industry
Product category
Regenerative Medicine
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112)
SIC
Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAC
3D Bioprinting & Biofabrication
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Regenerative medicine
  • Organ regeneration
  • Dental implants
  • Hair follicle regeneration
  • Artificial skin models

Where Organtech is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

Organtech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Bio-hybrid Tooth (Dental Implant) Products and Services: Revenue from periodontal ligament-integrated dental implants (Bio-hybrid Tooth) targeting dental clinics and hospitals. Currently in clinical research stage with a specific clinical study initiated in February 2025 at Minami Tohoku Medical Clinic. Revenue model involves medical device manufacturing and sales, and clinical service fees.
  2. Artificial Skin Licensing and Research Services: Revenue from licensing tension-providing 3D artificial skin manufacturing technology to pharmaceutical, cosmetics, and healthcare companies for drug safety testing, efficacy screening, and disease model development. Research support services for hair care and hair loss product development using human dermal papilla cells are also provided.
  3. Hair Follicle Regeneration Technology Licensing: Revenue from licensing domestic manufacturing rights for hair follicle cell-derived components including the third cell type (hair follicle regeneration-supporting cells), targeting alopecia treatment applications. Clinical translation strategy is ongoing toward hair restoration therapies.
  4. Research Support Services: Corporate research and development support services leveraging OrganTech's extensive life sciences expertise, covering healthcare and medical domains. Services include artificial skin manufacturing support, functional molecule screening system development, hair care and hair loss product development support, and general healthcare product development consulting.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Organtech product offering

Product offering

Core offering

OrganTech develops and commercializes proprietary organ regeneration technologies built on its foundational Organ Germ Method (器官原基法), a 3D stem cell manipulation technique. Its commercial portfolio consists of three product lines: Bio-hybrid Tooth (periodontal ligament-integrated dental implants), Hair Follicle Regeneration therapy using a three-cell configuration, and tension-providing 3D Artificial Skin models for pharmaceutical and cosmetics testing. The company also offers research support and licensing services to corporate R&D clients in healthcare and life sciences.

Product overview

OrganTech is a regenerative medicine company developing three core product lines based on its world-first organ regeneration technology: Bio-hybrid Tooth (dental implant with periodontal ligament), Hair Follicle Regeneration (hair loss treatment using stem cells), and Three-dimensional Artificial Skin (tension-loaded skin model for testing). The company operates as a platform of technologies anchored by the 'Organ Germ Method' developed in 2007, with all three products addressing quality of life (QOL) medical needs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bio-hybrid Tooth (バイオハイブリッドトゥース) A next-generation dental implant integrating a hydroxyapatite-coated titanium fixture with a regenerated periodontal ligament (periodontal ligament, cementum, and alveolar bone) derived from the patient's own residual tissue. It restores natural physiological tooth functions including shock absorption, proprioception, and immune defense that are absent in conventional osseointegration implants. Targeted at dental clinics, oral surgeons, and prosthodontists.
  • Hair Follicle Regeneration (毛髪再生) A regenerative therapy that reconstitutes functional hair follicles from a three-cell configuration: epithelial stem cells, mesenchymal dermal papilla cells, and a newly identified accessory mesenchymal cell (hair follicle regeneration-supporting cell) derived from the patient's own occipital hair. Designed for alopecia treatment including androgenetic alopecia, female pattern hair loss, alopecia areata, cicatricial alopecia, and drug-induced alopecia.
  • Three-dimensional Artificial Skin (三次元人工皮膚) The world's first 3D artificial skin model with applied mechanical tension, where epidermal and dermal cell orientation mimics natural skin and dramatically enhances cellular physiological function. Licensed to pharmaceutical, cosmetics, and healthcare companies for safety testing (skin irritation assays), high-sensitivity functional assays, mechanism analysis, and disease/damage model development.
  • Research Support Services (研究支援) Contract research and development services for corporate clients in healthcare and medical domains. Includes artificial skin manufacturing support, functional molecule screening system development, hair care and hair loss product development support using human dermal papilla cells, and general healthcare product development consulting leveraging OrganTech's life sciences expertise.

Quantifiable outcome

  • Osseointegration confirmed in all 4 enrolled patients; 3 evaluated at 24 weeks showed natural tooth-like test values and no inflammatory adverse events (periotest values within natural tooth range of 2-5)
  • +3 more outcomes

Companies that use Organtech

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Organtech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Organtech partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor, core and major.

  • MID-G (Medical Innovation and Dental Growth)minorChannel Partner/ Reseller/ Distributor · 17 April 2026OrganTech became a supporting member of MID-G, an organization that supports dental clinics in academic, educational, and business management areas. This partnership supports the company's Bio-hybrid Tooth go-to-market strategy.
  • RIKEN Center for Biosystems Dynamics Research (理化学研究所 生命機能科学研究センター)coreStrategic or Co-development Partner · 25 February 2026A long-standing research collaboration with RIKEN BDR, where OrganTech's founder Takashi Tsuji led the Organ Induction Research Team from 2014-2024. Joint research has produced the Organ Germ Method and multiple organ regeneration breakthroughs including the discovery of the accessory mesenchymal cell essential for hair follicle regeneration, published in Biochemical and Biophysical Research Communications in 2026.
  • Kojima Bio Co., Ltd. (コージンバイオ社)majorOEM/ Whitelabel/ Licensing Partner · 27 August 2025Licensing agreement for three-dimensional artificial skin technology with Kojima Bio Co., Ltd., enabling the company to manufacture and commercialize OrganTech's tension-providing 3D artificial skin for pharmaceutical, cosmetics, and healthcare applications.
  • QNova Inc.coreStrategic or Co-development Partner · 26 August 2025Partnership with US-based QNova Inc. to advance next-generation Bio-implant toward FDA regulatory approval and US market entry. QNova provides regulatory expertise and market access support for the FDA 510(k) pathway as a medical device.
  • Hillside Akasaka Dental Clinic (ヒルサイド赤坂デンタルクリニック)majorStrategic or Co-development Partner · 20 August 2025Clinical research site for next-generation Bio-implant in Tokyo, initiated August 2025 as part of OrganTech's multi-site clinical development strategy.
  • Undisclosed Japanese Partner (国内ライセンス先)majorOEM/ Whitelabel/ Licensing Partner · 20 May 2025Domestic manufacturing rights license for hair follicle cell-derived components including the third 'hair follicle regeneration-supporting' cell type for alopecia treatment applications.
  • Musashi Precision Co., Ltd. (武蔵精密工業株式会社)majorStrategic or Co-development Partner · 4 February 2025Business partnership for joint R&D of automated manufacturing equipment for 3D artificial skin models. Musashi Precision contributes manufacturing automation expertise while OrganTech provides the artificial skin technology platform.
  • Minami Tohoku Medical Clinic / Brain Surgery Disease General Institute (南東北医療クリニック / 脳神経疾患研究所附属総合南東北病院)coreStrategic or Co-development Partner · 29 January 2025Clinical research partnership for Bio-hybrid Tooth specified clinical study. Responsible physician Dr. Shohei Kasugai (formerly Tokyo Medical and Dental University) leads the study. The clinic conducted patient enrollment (completed October 2025) and reported positive interim results at 24-week evaluation for all 3 assessed patients.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Organtech competitors and assessment

Company assessment

Direct peers

  • Cyfuse Biomedical: Japanese 3D bioprinting company developing tissue-engineered products using its proprietary Kenzan method. Direct peer to OrganTech in 3D tissue engineering and biofabrication, with overlap in regenerative medicine product development in Japan.
  • J-TEC (Japan Tissue Engineering Co., Ltd.): Japanese regenerative medicine company commercializing autologous tissue-engineered products (cartilage, skin, cornea). Direct peer in the regenerative medicine/QOL product space, sharing the same Japanese regulatory environment and commercialization model via cell-based therapies.
  • Organovo Holdings: US-based 3D bioprinting company developing human tissue models for drug discovery and therapeutic applications. Comparable to OrganTech's 3D Artificial Skin program, both leveraging biofabrication to create human-relevant tissue models for pharma and cosmetics testing.
  • Stemson Therapeutics: US-based biotech developing iPSC-derived hair follicle regeneration therapies for androgenetic alopecia. Directly comparable to OrganTech's Hair Follicle Regeneration program as both pursue cellular regeneration of hair follicles rather than transplantation or drugs.
  • Toregem BioPharma: A Japanese clinical-stage biotech developing tooth regeneration therapies using anti-USAG-1 antibody technology. Directly comparable to OrganTech as one of very few companies globally pursuing biological tooth regeneration, with overlapping target patient populations and similar pre-commercial stage.
  • CellSeed: Japanese regenerative medicine company developing temperature-responsive cell cultureware and epithelial sheet products for regenerative applications. Comparable to OrganTech as a Japan-based regenerative medicine company pursuing cell-based tissue products in adjacent regenerative indications.

Broad incumbents

  • Straumann Group: Global leader in dental implants and restorative dentistry with extensive surgeon training, distribution, and brand recognition. Relevant broad incumbent in the dental implant market that OrganTech's Bio-hybrid Tooth would need to displace or differentiate against upon commercialization.
  • MiMedx Group: US-listed regenerative medicine company commercializing placental tissue allografts for wound healing and surgical recovery. Comparable to OrganTech as a broad regenerative medicine commercializer, though focused on a different tissue modality and existing US commercial scale.
  • Integra LifeSciences: Global medical device company with broad regenerative technology and tissue products portfolio including dermal regeneration templates. Comparable as a broad incumbent offering overlapping regenerative skin/tissue solutions, though at much larger scale and via different (scaffold-based) technology.

Emerging players

  • Medipost: Korean stem cell therapeutics company commercializing Cartistem and other umbilical cord blood-derived stem cell products. Comparable to OrganTech as an Asian stem cell therapeutics developer with both regenerative and tissue-engineering programs targeting similar QOL indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Organtech social profiles

Digital presence

Organtech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Organtech leadership team

Management profile

Number of profiles

Profiles4 records

Organtech funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Organtech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Organtech

What does Organtech do?

OrganTech develops and commercializes proprietary organ regeneration technologies built on its foundational Organ Germ Method (器官原基法), a 3D stem cell manipulation technique. Its commercial portfolio consists of three product lines: Bio-hybrid Tooth (periodontal ligament-integrated dental implants), Hair Follicle Regeneration therapy using a three-cell configuration, and tension-providing 3D Artificial Skin models for pharmaceutical and cosmetics testing. The company also offers research support and licensing services to corporate R&D clients in healthcare and life sciences.

Is Organtech a public or private company?

Organtech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Organtech founded?

Organtech was founded in 2023. It employs 1 to 10 people.

Where is Organtech based?

Organtech is headquartered in Tokyo, Japan, in the Asia region.

How does Organtech make money?

Four revenue lines are on record. Bio-hybrid Tooth (Dental Implant) Products and Services are the primary driver. The others are artificial Skin Licensing and Research Services, hair Follicle Regeneration Technology Licensing and research Support Services.

Who are Organtech's main competitors?

Direct peers on record are Cyfuse Biomedical, J-TEC (Japan Tissue Engineering Co., Ltd.), Organovo Holdings, Stemson Therapeutics, Toregem BioPharma and CellSeed. Broad incumbents are Straumann Group, MiMedx Group and Integra LifeSciences. Medipost is listed as an emerging player.

Does Organtech have an API?

No public API is recorded for Organtech.

What industry is Organtech in?

Organtech's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAGAC, 3D Bioprinting & Biofabrication. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrtimesSwiss Bioscience社と毛髪再生技術の欧州展開に向けた戦略的協業に関するMOUを締結Organ-Tech and Swiss Bioscience signed a non-binding MOU to explore strategic collaboration on hair regeneration technology in Europe. Organ-Tech will leverage its hair regeneration research and Swiss Bioscience's GMP manufacturing and clinical research capabilities. The first step involves licensing and transferring culture supernatant technology from hair follicle cells.EIN PresswireHair of Istanbul Publishes Patient Education Guide to OrganTech's Hair Follicle Regeneration ResearchHair of Istanbul published a patient education guide summarizing OrganTech's hair follicle regeneration research, based on written responses from the company. OrganTech reported generating hair follicles from adult mouse cells in February 2026, but the approaches have not reached clinical use in humans. The guide distinguishes between cell transplantation and organ regeneration, noting both remain experimental.BioSpaceSwiss Bioscience and OrganTech sign MOU to explore strategic collaboration in hair regeneration in EuropeSwiss Bioscience and OrganTech signed a non-binding MOU to explore collaboration on OrganTech's hair regeneration technologies in Europe. OrganTech selected Swiss Bioscience as its preferred European partner for regulatory development, GMP manufacturing, clinical research, and potential commercialization. The initial focus is on conditioned medium from allogeneic hair follicle cells, with plans for broader strategic partnership.The Times of IndiaThird Cell To Grow Hair: Japanese scientists discover a ‘third cell’ that helps regrow hair naturally; new study promises an effective solution for hair loss - The Times of IndiaJapanese scientists at RIKEN Institute and Tokyo-based OrganTech have identified a previously unknown third cell type—around-bulge mesenchyme (ABM) cells—that, when combined with two already known cell types, successfully recreated the complete hair-growth cycle in mice for the first time. The discovery, published in Biochemical and Biophysical Research Communications, addresses a nearly two-decade gap in organ regeneration research by revealing a missing cellular component that the body naturally supplies during hair follicle function. According to OrganTech CEO Yoshio Shimo, the findings establish a foundational cellular configuration for functional hair follicle regeneration and reinforce the broader strategy of organ-level regenerative medicine.Longevity.TechnologyJapanese startup makes hair follicle regeneration breakthroughJapanese regenerative medicine company OrganTech, in collaboration with researchers at the RIKEN Center for Biosystems Dynamics Research, has identified a previously uncharacterized cell type that, when combined with two known stem cell types, enables the regeneration of fully functional hair follicles in laboratory conditions. The three-cell configuration, which includes an "accessory" mesenchymal cell essential for triggering the transition from resting to growth phase, was shown to sustain hair production over time following transplantation into mice. While currently preclinical, the findings published in Biochemical and Biophysical Research Communications provide a potential blueprint for hair restoration therapies and support the company's broader strategy in organ-level regenerative medicine.GlobeNewswireOrganTech Defines Minimal Stem Cell Set Enabling Functional Hair Follicle Regeneration In VitroOrganTech, Inc. announced that its research team has defined a minimal stem cell set required for functional hair follicle regeneration in vitro, published in Biochemical and Biophysical Research Communications. The study identified an accessory mesenchymal cell population as essential for reconstructing fully functional hair follicles, demonstrating sustained downgrowth and hair shaft production under defined conditions. The company is advancing a clinical translation strategy targeting alopecia and related regenerative indications, with the global hair restoration market projected to exceed $15 billion.YahooOrganTech Defines Minimal Stem Cell Set Enabling Functional Hair Follicle Regeneration In VitroOrganTech, Inc. announced that its research team has identified a minimal set of three stem cell types required to regenerate functional hair follicles in vitro, validating its organ-level regeneration platform. The study highlights the essential role of an accessory mesenchymal cell population in achieving sustained hair shaft production, distinguishing this biological approach from current pharmacological treatments like minoxidil.PrtimesHair regeneration outside the body by three types of stem cells from adult hair follicles.A joint research team from OrganTech Co., Ltd. and RIKEN discovered a new cell population called hair follicle regeneration-supporting cells, identifying this as a third cell type essential for hair follicle development, growth, and regeneration. Using three types of adult-derived stem cells, the team successfully regenerated functional hair follicles outside the body that produced hair growth and maintained normal hair cycles. The research was published in the journal Biochemical and Biophysical Research Communications and is expected to contribute to regenerative medicine treatments for alopecia.The Japan TimesJapan-led cell discovery hints at potential new treatments for hair lossResearchers in Japan, led by the national scientific research institute Riken and Tokyo-based startup OrganTech, have identified a previously unknown "third cell" essential for regenerating hair follicles. The team successfully re-created the complete hair-growth cycle in mice by adding this newly identified cell type to two already known components of hair follicles. The findings, published in Biochemical and Biophysical Research Communications, represent a step toward potential new treatments for hair loss.